Replies to post #800314 on NorthWest Biotherapeutics Inc (NWBO)

[SkyLimit2022]

suit,

Thanks for highlighting the importance of “putting out the truth” 😶

Fact ✅️: Authorized share increases are normal for companies planning ongoing or expanded operations. No dilution occurs unless & until those shares are actually issued…

Authorized shares are not issued shares.

Having authorized shares is strategic & preserves a range of options & flexibility for future needs which may include partnerships, negotiating deals, or otherwise expanding the company.

Fact ✅️: Regarding the P3, enrollment completed years before 2020, but patients continued to be treated & followed under the trial protocol as trial participants after enrollment closed. The P3 trial concluded in 2020, & data lock happened in Q4 of 2020.

NICE UK 🇬🇧 DCVax-L

Fud Flood 🌊

[Investor082]

.10 share price with 2.7B outstanding shares would give the company a $270M market cap. Thats going to be a rich valuation without NICE reimbursement and FDA BLA submission. Without NICE approval, they wont exceed $10-15M annual revenue. At a generous 6X revenue, you are looking at under $100M market cap in that case. So, a share price of under .05 is likely in the first half of 2027, if not sooner.

[AllSheWrote]

It seems more and more clear that NWBO never intended to submit the DCVax-L trial results to the FDA, and that maybe focusing on Europe alone was the plan from the beginning. Do you think any of the longs here invested with that understanding?